Global Prosthetic Heart Valves Market – Insights Prosthetic heart valve refers to a device implanted in the heart of a patient suffering from valvular heart disease. Replacement of a diseased valve with a prosthetic heart valve results in reduction in morbidity and mortality associated with the cardiac valve disorder. When the treatment of heart valve disease reaches a stage where it does not provide relief to the patient, then surgery recommended as the best alternative to repair or replace the valve.
In case of a valve replacement surgery, carbon based mechanical valves and biological tissue valve are the types of valves that can be selected based on the condition. On the basis of product type, the global prosthetic heart valve market can be segmented into mechanical heart valves, transcatheter heart valves, and tissue heart valves. Tissue heart valves are harvested from pig heart valves and cow heart sac. The life of a tissue valve is 10 to 15 years. Advancements in technology and increasing prevalence of heart valve diseases are some major factors projected to drive growth of the prosthetic heart valve market in the near future.

Request A Sample Copy:http://bit.ly/2N1UYEO

The global prosthetic heart valves market is valued at US$ 3,622.72 million in 2017 and is expected to witness a CAGR of 11.2% over the forecast period (2017 – 2025).

Growing Aging Population and prevalence of valvular disease spur growth of the prosthetic heart valve market
Increasing geriatric population and prevalence of valvular heart disease will boost the demand of prosthetic heart valves market. According to the National Centre for Health Statistics, 2011, Heart disease is the leading cause of death in the U.S., killing more than 600,000 Americans each year. Continue focusing to advance surgical replacement technologies for patients with diseased, damaged or malfunctioning heart valves by manufacturers is expected to create a lucrative opportunities for the market over the forecast period. For instance, in 2017, Edwards Lifesciences Corporation received U.S. FDA approval for aortic and mitral valve-in-valve procedures using the Edwards SAPIEN 3 transcatheter heart valve.
The SAPIEN 3 valve is the first transcatheter heart valve approved in the U.S. for the treatment of both aortic and mitral patients who are at high risk for a subsequent open-heart surgery to replace their bioprosthetic valve. On the contrary, the high costs associated with the devices mainly transcatheter aortic valve replacement devices and stringent government regulations may hamper the growth of the market.

The growth of prosthetic heart valve market size in Asia is expected to be high in the near future due to increasing incidence of various chronic diseases and improving healthcare infrastructure in this region. According to a study published in the Lancet—a U.K.-based medical journal, 2016—the number of people affected by high blood pressure has almost doubled over past 40 years (from 1975 to 2015) worldwide. However, the largest rise in the prevalence of adults with high blood pressure has been in low- and middle-income countries (LMICs) in south Asia (eg, Bangladesh and Nepal) and sub-Saharan Africa (eg, Ethiopia and Malawi). Moreover, in according to EurekAlert global news, In 2015, over half (590 million) of adults with high blood pressure lived in east, southeast and south Asia--of whom 199 million lived in India and 226 million in China.

The key players operating in the global prosthetic heart valves market include Boston Scientific Corporation, Edwards Lifesciences Corporation, Medtronic plc, LivaNova PLC, Abbott, Jenavalve Technology, Inc., Lepu Medical Technology Co., Ltd., CryoLife, Inc., and Neovasc Inc.
Click To Read More On prosthetic heart valves market
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:[email protected]